DEEPMATTER GROUP PLC | RNS Reach Story | ||
| Go to market news section | ||
|
DeepMatter Group plc
('DeepMatter')
Collaboration with AstraZeneca
DeepMatter announces collaboration with AstraZeneca focused on improving productivity of compound synthesis using digital technologies enabled with machine learning and artificial intelligence
DeepMatter's DigitalGlassware™ data collection and structuring technology to be used alongside AstraZeneca's automated compound synthesis platform
09 December 2019: DeepMatter today announces a collaboration with AstraZeneca to use innovative digital technologies with the aim of improving the productivity and reproducibility of compound synthesis.
Scientists from the two organisations will work together to improve the productivity of synthesising single compounds and compound libraries based on unique, structured data harvested from the DigitalGlassware™ technology.
The conditions of a reaction, such as temperature, solvent and catalysts, are important to the success of any experiment. DigitalGlassware™ allows users to capture and analyse a rich array of information about their chemical reaction. A unique multi-sensor probe sits inside the reaction vessel, providing real-time data (temperature, pressure, UV light levels and more) while an environmental sensor records ambient conditions. Data from external laboratory hardware can also be recorded through software application programming interfaces (APIs).
These structured data are collected and stored in the cloud alongside each process carried out during the reaction, contextualising the actions of the user in the lab. Displayed in real time, the data can be interrogated using multiple views, enabling the analysis of reaction runs and the re-playing of syntheses. By capturing in-situ chemical data alongside the experimental intent, observations and outcomes, it is expected that machine learning and AI algorithms could yield cost and time savings whilst also providing novel insights into chemistry.
Michael Kossenjans, Associate Director, Discovery Sciences, R&D, AstraZeneca, said:
'Our goal is to transform drug design using innovative digital technologies in combination with automation and AI. To get potential new medicines to patients faster, we need to reduce the cycle time for lead identification and optimisation and look forward to working with DeepMatter to assess the potential of DigitalGlassware™ to help with this.'
Mark Warne, CEO of DeepMatter, said:
'We've been impressed with the automated chemistry platforms developed at AstraZeneca sites for autonomous delivery of new lead series. We see an opportunity to draw together knowledge from the DigitalGlassware™ platform to enable machine learning and AI technologies to increase the certainty of producing a high quality and choice of candidate drug molecules.
'We look forward to progressing this exciting collaboration over the coming months as we continue to maximise the potential of the DigitalGlassware™ platform.'
For further information, please contact:
DeepMatter Group plc | T: 0141 548 8156 |
Mark Warne, Chief Executive Officer | |
Shore Capital (Nominated Adviser and Broker) | T: 020 7408 4050 |
Tom Griffiths David Coaten | |
Alma PR Caroline Forde Jessica Joynson Kieran Breheny | T: 020 3405 0205 deepmatter@almapr.co.uk |
About Deepmatter Group
DeepMatter's long term strategy is to integrate chemistry with technology, thereby enabling a greater use of artificial intelligence and reaching a point where chemicals can be autonomously synthesised through robotics. In the near term this involves the provision of an integrated software, hardware and artificial intelligence enabled platform, DigitalGlassware™, to scientists across research and process development sectors.
The DigitalGlassware™ platform allows chemistry experiments to be accurately and systematically recorded, coded and entered into a shared data cloud. The platform is designed to enable chemists to work together effectively; sharing the details of their experiments from anywhere and in real-time, so that work is not needlessly duplicated, time and money wasted, and ultimately so new discoveries may be made faster.
Visit:www.deepmatter.ioand follow @deepmattergroup
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
| London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply. |
| ©2014London Stock Exchange plc. All rights reserved |
DeepMatter collaboration with AstraZeneca - RNS
Attachments
- Original document
- Permalink
Disclaimer
Deepmatter Group plc published this content on 09 December 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 December 2019 07:05:07 UTC
